MLN4924 and Neddylation: Unraveling E2 Enzyme Selectivity in Tumor Models

Introduction

The ubiquitin-proteasome system and associated post-translational modifications, such as neddylation, orchestrate the fate and function of myriad cellular proteins. Neddylation, the covalent attachment of NEDD8 to substrate lysines, is essential for activation of cullin-RING ligases (CRLs), which in turn regulate protein ubiquitination and degradation. Dysregulation of the neddylation cascade is increasingly recognized as a driver of tumorigenesis and other pathologies, especially in the context of solid tumor models. As research delves deeper into the molecular intricacies of neddylation, small-molecule inhibitors such as MLN4924 have become indispensable tools for cancer biology research and anti-cancer therapeutic development.

Neddylation Pathway Overview and the Role of E2 Enzyme Selectivity

The neddylation cascade mirrors ubiquitination, employing a three-enzyme system: E1 (NEDD8-activating enzyme, NAE), E2 (NEDD8-conjugating enzymes, NCEs), and E3 ligases. Notably, mammalian cells express only two NEDD8 E2 enzymes: UBE2M (UBC12) and UBE2F. UBE2M primarily conjugates NEDD8 to cullins 1-4 via RBX1, activating CRLs1-4, while UBE2F, in conjunction with SAG/RBX2, neddylates cullin-5 and other non-cullin substrates, such as RHEB, as recently demonstrated (Zhang et al., 2025).

Selective inhibition of this cascade offers a precise strategy to dissect downstream effects of neddylation in cell cycle regulation and tumor growth. However, the complexity of E2 enzyme selectivity and the existence of both cullin and non-cullin neddylation substrates have posed challenges to the interpretation of pathway inhibition in vivo. This underscores the need for potent, selective inhibitors and rigorous mechanistic studies.

MLN4924: Mechanism, Selectivity, and Technical Properties

MLN4924 (SKU: B1036) is a potent, selective inhibitor of the NEDD8-activating enzyme (NAE), with an IC₅₀ of 4 nM. By competitively binding the nucleotide-binding site of NAE, MLN4924 blocks NEDD8 activation and transfer to E2 enzymes, halting the formation of Ubc12–NEDD8 thioester and subsequent NEDD8–cullin conjugates. This results in global inhibition of CRL-mediated ubiquitination, leading to accumulation of substrates such as CDT1 and pronounced cell cycle defects—effects that are both dose- and context-dependent. MLN4924’s selectivity profile is distinguished by its substantially higher IC₅₀ values for related enzymes (UAE, SAE, UBA6, ATG7), underscoring its utility as a highly selective NAE inhibitor for cancer research.

In cellular assays, MLN4924 induces dose-dependent inhibition of NAE activity, while in vivo studies in xenograft models (e.g., HCT-116 colon, H522 lung, Calu-6 lung tumors) demonstrate significant tumor growth inhibition at 30–60 mg/kg with good tolerability. The compound is a solid (MW 443.53), soluble in DMSO (≥22.18 mg/mL) and ethanol (≥42.2 mg/mL), but insoluble in water, and is recommended for short-term solution storage at –20°C. These characteristics make MLN4924 a practical and reliable tool for probing neddylation in cell-based and animal studies.

RHEB Neddylation and the UBE2F-SAG Axis: New Insights from Recent Research

Emerging evidence has expanded the neddylation landscape beyond cullin substrates. In their recent study, Zhang et al. (2025) identified the small GTPase RHEB as a direct neddylation substrate of UBE2F-SAG. The neddylation of RHEB at K169 enhances its lysosomal localization and GTP-binding affinity, thereby potentiating mTORC1 activity—a key regulator of cell growth, metabolism, and autophagy. UBE2F depletion in cell culture resulted in mTORC1 inactivation, cell cycle arrest, and increased autophagy. In vivo, liver-specific Ube2f knockout attenuated tumorigenesis in PTEN-deficient mice, suggesting that UBE2F-driven neddylation is a pro-tumorigenic mechanism in hepatocellular carcinoma (HCC).

These findings underscore the dual role of neddylation in regulating both cullin-dependent and cullin-independent (e.g., RHEB-mediated) oncogenic signaling. Moreover, they highlight the therapeutic promise of neddylation pathway inhibition for targeting not only classical CRL substrates but also non-cullin effectors that modulate critical pathways such as mTORC1.

MLN4924 as a Tool to Dissect E2 Enzyme Specificity in Neddylation Inhibition

Given its ability to block NAE, MLN4924 inhibits both UBE2M- and UBE2F-dependent neddylation events, providing a system-wide shutdown of neddylation. This is particularly valuable in teasing apart the individual contributions of CRL-mediated ubiquitination and non-cullin substrate modification. For instance, in the context of RHEB neddylation and mTORC1 activation, MLN4924 not only suppresses CRL activity but may also attenuate UBE2F-SAG–driven RHEB neddylation, thereby providing a dual blockade of tumor-promoting pathways.

Such broad-spectrum inhibition enables researchers to study crosstalk between the ubiquitin-proteasome system, neddylation, and key signaling axes like mTORC1 in cancer biology research. Importantly, MLN4924’s selectivity profile ensures minimal off-target effects on other ubiquitin-like pathways, enhancing the interpretability of experimental outcomes in solid tumor models and cell cycle regulation assays.

Experimental Considerations: Dosing, Solubility, and Model Systems

For effective neddylation pathway inhibition in vitro, MLN4924 is typically applied to cell lines such as HCT-116 at nanomolar to low micromolar concentrations, with robust inhibition of NAE activity and downstream CRL substrates (e.g., CDT1). In vivo, MLN4924 demonstrates potent tumor growth inhibition in xenograft models at 30–60 mg/kg when administered subcutaneously, with minimal impact on animal weight and overall health. Its pharmacokinetic and pharmacodynamic properties support short-term dosing regimens and facilitate studies in both cell culture and animal models.

Due to its poor water solubility, MLN4924 should be formulated in DMSO or ethanol for both stock solutions and in vivo dosing vehicles. Solutions should be freshly prepared and stored at –20°C for optimal stability. These technical parameters are critical for ensuring reproducibility and maximizing the interpretability of results in studies targeting the neddylation pathway.

Therapeutic Implications: From Mechanism to Anti-Cancer Strategy

The insights from the UBE2F-SAG–RHEB–mTORC1 axis reinforce the rationale for NAE inhibition as a multi-faceted anti-cancer approach. By suppressing neddylation of both CRL cullins and non-cullin substrates such as RHEB, MLN4924 disrupts cellular processes vital for tumor cell proliferation, survival, and metabolic adaptation. This is especially pertinent in cancers characterized by hyperactive mTORC1 signaling, such as HCC, where neddylation pathway inhibition may offer synergistic benefits alongside other targeted therapies.

Moreover, the selectivity of MLN4924 for NAE over other activating enzymes reduces the confounding effects of off-target inhibition, making it a preferred agent for preclinical studies focused on the neddylation pathway. Its efficacy in diverse solid tumor models supports its application in translational research aimed at novel anti-cancer therapeutic development.

Conclusion

MLN4924 stands at the forefront of chemical biology tools for dissecting the neddylation pathway, offering unparalleled selectivity for the NEDD8-activating enzyme. The recent elucidation of non-cullin neddylation substrates such as RHEB, and their roles in oncogenic signaling via the UBE2F-SAG axis, further expands the potential of MLN4924 in cancer research. By enabling researchers to probe both cullin-RING ligase ubiquitination inhibition and mTORC1-related mechanisms, MLN4924 facilitates a deeper understanding of cell cycle regulation and tumor biology in solid tumor models.

While previous articles such as MLN4924: Targeting Neddylation Pathways for Solid Tumor Research have primarily emphasized MLN4924’s impact on cullin-RING ligase activity and classical neddylation targets, this article extends the discussion by critically examining recent advances in E2 enzyme selectivity and the emerging role of non-cullin substrates like RHEB in tumorigenesis. By integrating findings from Zhang et al. (2025), we highlight novel mechanistic insights and practical guidance for leveraging MLN4924 in the study of complex oncogenic networks and anti-cancer therapeutic development.